SHANGHAI, April 8 2022 — WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, received an ESG Risk Rating, recognizing it as a “Top Rated” performing company from Sustainalytics as of March, 2022. WuXi AppTec placed in the top 4 percent of the global pharmaceutical industry with a “Low Risk” of experiencing material financial impacts from ESG factors. The strong performance reflects its commitment to Environmental, Social and Governance (ESG) initiatives.
Throughout 2021, WuXi AppTec has enhanced its management system to identify and integrate hundreds of ESG-related measures across its global operations. These initiatives were also evaluated in Sustainalytics’ latest ESG Risk ratings report, which shows that WuXi AppTec has made significant progress in the areas of Business Ethics, Emissions, Effluents and Waste, Occupational Health and Safety, Human Capital and Corporate Governance.
“We welcome Sustainalytics’ assessment of WuXi AppTec’s ESG progress,” said Edward Hu, Vice Chairman of WuXi AppTec and Chairman of WuXi AppTec’s ESG Committee. “We will continue to prioritize ESG initiatives while enabling our customers’ discovery, development and manufacturing of new medicines and groundbreaking therapies for patients worldwide.”
Sustainalytics is a leading ESG research, ratings and data firm that supports investors around the world with the development and implementation of responsible investment strategies. Sustainalytics’ ESG Risk Ratings span more than 14,000 global companies on their exposure to industry-specific material ESG risks and how well they are managing those risks.